Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow APVO
Aptevo Therapeutics Inc. (APVO) Altman Z-score
Aptevo Therapeutics Inc.'s Altman Z-score for fiscal 2022 is 256174.47, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2022 | 256174.47 | 21,931.11 |
| FY2021 | 234243.36 | (948,411.75) |
| FY2020 | 1182655.11 | 956,366.25 |
| FY2019 | 226288.86 | (3,566,777.46) |
| FY2018 | 3793066.32 | (8,941,326.18) |
| FY2017 | 12734392.50 | 6,846,651.09 |
| FY2016 | 5887741.41 | — |
How fiscal 2022’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.55 | — | 0.66 | |
| Retained earnings / total assets | (6.02) | — | −8.43 | |
| EBIT / total assets | (0.84) | — | −2.76 | |
| Market value of equity / total liabilities | 426,974.86 | — | 256184.92 | |
| Sales / total assets | 0.09 | — | 0.09 | |
| Altman Z-score | Safe zone | 256174.47 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −20.50 | ||
Z and Z″ put Aptevo Therapeutics Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| APVO Aptevo Therapeutics Inc. | 256,174× |
| EOCN Eocene Ltd. compare | 26.9× |
| DCOY Decoy Therapeutics Inc compare | 4.3× |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | −15.9× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | −78.4× |
| CLDI Calidi Biotherapeutics, Inc. compare | −85.8× |
| GRI GRI Bio, Inc. compare | — |
| REVB Revelation Biosciences, Inc. compare | — |
| ARAV ARAVIVE, INC compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets